Replies to post #27 on Off the Radar.Nasdaq

[mick]

Nov 23, 2009 06:30 Vical Completes Final Patient Follow-Up in TransVax(TM) CMV Vaccine Phase 2 Trial
Vical Incorporated (Nasdaq:VICL) announced today that the company has completed the last scheduled follow-up visit for the final patient enrolled in a Phase 2 trial of its TransVax(TM) cytomegalovirus (CMV) vaccine in hematopoietic stem cell transplant (HCT) recipients. The company expects to have data available in the first half of 2010. continued...